Induction therapy in heart transplantation: Where are we now?

Transplant International

Volumn 26, Issue 7, 2013, Pages 684-695

  Aliabadi, Arezu ^a   Grömmer, Martina ^a   Cochrane, Adam ^b   Salameh, Olivia ^a   Zuckermann, Andreas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

antithymocyte globulin; basiliximab; efficacy; heart transplantation; induction; infection; malignancy; polyclonal; randomized; Thymoglobuline

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CORTICOSTEROID; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; THYMOCYTE ANTIBODY;

ANTIBODY MEDIATED REJECTION; CARDIAC ALLOGRAFT VASCULOPATHY; DRUG MEGADOSE; DRUG SAFETY; EFFUSION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEFT VENTRICULAR ASSIST DEVICE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PATIENT SELECTION; PERIPHERAL EDEMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SENSITIZATION; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

ANTILYMPHOCYTE SERUM; CALCINEURIN; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879024556     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12107     Document Type: Review

References (62)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al,. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2010. J Heart Lung Transplant 2010; 29: 1089.
2. Bonnefoy-Bérard N, Revillard JP,. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Trans 1996; 15: 435.
3. Bourdage JS, Hamlin DM,. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194.
4. Rebellato LM, Gross U, Verbanac KM, Thomas JM,. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57: 685.
5. Préville X, Flacher M, LeMauff B, et al,. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a non-human primate model. Transplantation 2001; 71: 460.
6. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N,. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360.
7. Teuteberg J, Shullo M, Zomak R, et al,. Alemtuzumab induction prior to cardiac transplantation with lower intensity immunosuppression: one-year outcomes. Am J Transplant 2010; 10: 382.
8. Das B, Shoemaker L, Recto M, Austin E, Dowling R,. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant 2008; 27: 242.
9. Pham SM, Jimenez J, Bednar BM, et al,. Campath-1H in clinical heart transplantation. J Heart Lung Transplant 2006; 25 (2 Suppl.): S228.
10. Zuckermann AO, Grimm M, Czerny M, et al,. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000; 69: 1890.
11. Schnetzler B, Leger P, Völp A, Dorent R, Pavie A, Gandjbakhch I,. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int 2002; 15: 317.
12. Mehra MR, Zucker MJ, Wagoner L, et al,. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24: 1297.
13. Beniaminovitz A, Itescu S, Lietz K, et al,. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613.
14. Mattei M, Redonnet M, Gandjbakhch I, et al,. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 26: 693.
15. Carrier M, Leblanc MH, Perrault LP, et al,. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 26: 258.
16. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH,. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 2006; 25: 1358.
17. Carlsen J, Johansen M, Boesgaard S, et al,. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 2005; 24: 296.
18. Chou N, Wang S, Chen Y, et al,. Induction immunosuppression with basiliximab in heart transplantation. Transpl Proc 2008; 40: 2623.
19. Rosenberg PB, Vriesendorp AE, Drazner MH, et al,. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24: 1327.
20. Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ,. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 2005; 24: 166.
21. Cantarovich M, Giannetti N, Barkun J, Cecere R,. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78: 779.
22. Sanchez-Lazaro IJ, Almenar-Bonet L, Martinez-Dolz L, et al,. Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction. Rev Esp Cardiol 2011; 64: 237.
23. Larson TS, Dean PG, Stegall MD, et al,. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
24. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
25. Flechner SM, Glyda M, Cockfield S, et al,. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
26. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
27. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
28. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I,. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5: 827.
29. González-Vílchez F, de Prada JA, Exposito V, et al,. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27: 1135.
30. Schmauss D, Weis M,. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131.
31. Walther S, Beiras-Fernandez A, Csapo C, et al,. Influence of polyclonal antithymocyte globulins on the expression of adhesion molecules of isolated human umbilical vein endothelial cells. Transplantation Proc 2010; 42: 1931.
32. Beiras-Fernandez A, Chappell S, Hammer C, Beiras A, Reichart B, Thein E,. Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl Immunol 2009; 20: 224.
33. Beiras-Fernandez A, Thein E, Chappell D, et al,. Polyclonal anti-thymocyte globulins influence apoptosis in reperfused tissues after ischemia in a non-human primate model. Transpl Int 2004; 17: 453.
34. Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y,. The role of Thymoglobuline induction in kidney transplantation: an update. Clin Transplant 2012; 26: E450.
35. Taylor DO, Edwards LB, Boucek MM, et al,. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25: 869.
36. Zuckermann A, Ploner M, Czerny M, et al,. Low incidence of graft arteriosclerosis after cardiac transplantation: risk factor analysis for patients with induction therapy. Transplantation Proc 2002; 34: 1869.
37. Carrier M, White M, Perrault LP, et al,. A 10-year experience with intravenous Thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999; 18: 1218.
38. Zhang R, Haverich A, Strüber M, Simon A, Bara C,. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant 2008; 27: 603.
39. Faggian G, Forni A, Milano AD, et al,. Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. Transplant Proc 2010; 42: 3679.
40. Adamson R, Obispo E, Dychter S, et al,. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplant Proc 1998; 30: 1107.
41. Carrier M, Jenicek M, Pelletier LC,. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis. Transplant Proc 1992; 24: 2586.
42. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O,. Review article: use of induction therapy in liver transplantation. Transplant Rev (Orlando) 2012; 26: 246.
43. Emin A, Rogers C, Thekkudan J, Bonser RS, Banner NR, Steering Group, UK Cardiothoracic Transplant Audit. Antithymocyte globulin therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant 2011; 30: 770.
44. Gajarski R, Blume E, Urschel S, et al,. Infection and malignancy after pediatric transplantation: the role of induction therapy. J Heart Lung Transplant 2011; 30: 299.
45. Hershberger RE, Starling RC, Eisen HJ, et al,. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352: 2705.
46. McKeage K, McCormack PL,. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs 2010; 24: 55.
47. Møller C, Gustafsson F, Gluud C, Ross H, Delgado DH,. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 2008; 27: 835.
48. Opelz G, Döhler B,. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
49. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al,. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
50. Gao SZ, Chaparro SV, Perlroth M, et al,. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22: 505.
51. O'Neill JO, Edwards LB, Taylor DO,. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186.
52. El-Hamamsy I, Stevens LM, Carrier M, et al,. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 2005; 18: 1280.
53. Dayton J, Richmond M, Weintraub R, Shipp AT, Orjuela M, Addonizio LJ,. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric transplant patients. J Heart Lung Transplant 2011; 30: 420.
54. Ramirez CB, Marino IR,. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 2007; 7: 137.
55. Nair N, Ball T, Uber PA, Mehra MR,. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant 2011; 30: 612.
56. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH,. Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol 2003; 18: 153.
57. Kobashigawa JA, Sabad A, Drinkwater D, et al,. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996; 94 (9 suppl.): II294.
58. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV,. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 1556.
59. Kobashigawa J, Mehra M, West L, et al,. Consensus Conference Participants. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28: 213.
60. Goland S, Lawrence S, Czer C, et al,. Induction therapy with Thymoglobuline after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant 2008; 27: 1115.
61. Koch A, Daniel V, Dengler T, Schnabel PA, Hagl S, Sack FU,. Effectivity of a t-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant 2005; 24: 708.
62. Krasinskas AM, Kreisel D, Acker MA, et al,. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation 2002; 73: 1339.